Kees Bol

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

Judith E. Karp, Jeffrey E. Lancet, Scott H. Kaufmann et al. · Blood · 2001 · 445 citations · Full text

Medicine, Oncology, Pharmacology +9

JNJ-26481585, a Novel Second-Generation Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity

Janine Arts, Peter King, Ann Marin et al. · Clinical Cancer Research · 2009 · 232 citations

Medicine, Oncology, Pharmacology +12

First-in-human phase 1/2 study of MCLA-128, a full length IgG1 bispecific antibody targeting HER2 and HER3: Final phase 1 data and preliminary activity in HER2+ metastatic breast cancer (MBC).

María Alsina, Valentina Boni, Jan H.M. Schellens et al. · Journal of Clinical Oncology · 2017 · 44 citations

Medicine, Oncology, Pharmacology +17

Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose

Aurelia H. M. de Vries Schultink, Robert P. Doornbos, Alexander B. H. Bakker et al. · Investigational New Drugs · 2018 · 34 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +17

Clinical activity of MCLA-128 (zenocutuzumab) in combination with endocrine therapy (ET) in ER+/HER2-low, non-amplified metastatic breast cancer (MBC) patients (pts) with ET-resistant disease who had progressed on a CDK4/6 inhibitor (CDK4/6i).

Barbara Pistilli, Hans Wildiers, Erika Hamilton et al. · Journal of Clinical Oncology · 2020 · 34 citations

Medicine, Oncology, Pharmacology +17